The Effects of COVID-19 on the Dispensing Rates of Antidepressants and Benzodiazepines in Canada

Overview

Journal Depress Anxiety

Publisher Wiley

Date 2021 Nov 29

PMID 34843627

Citations 13

Authors

Sunjeev Uthayakumar

Mina Tadrous

Simone N Vigod

Sophie A Kitchen

Tara Gomes

Affiliations

Soon will be listed here.

Abstract

Background: Population studies have shown that rates of depressive and anxious symptoms have increased as a result of COVID-19. We analyzed trends in the dispensing rates of antidepressants and benzodiazepines in Canada to determine whether the pandemic has caused changes in rates of pharmacological treatment for depression and anxiety.

Methods: We conducted a population-based, cross-sectional time-series analysis of antidepressants and benzodiazepines dispensed monthly by Canadian community pharmacies between January 2017 and December 2020. We used March 2020 as the intervention month to determine if there were any significant changes in the national rate of antidepressant and benzodiazepine tablets dispensed as the result of the COVID-19 pandemic.

Results: There was a temporary reduction in the dispensing rate of antidepressants in April 2020 (from 489 tablets per 100 in March 2020 to 356 tablets per 100 in April 2020; p ≤ .0001); however, the rate returned to its previous level by August 2020. There were no detectable deviations in benzodiazepine dispensing after the declaration of the state of emergency in Ontario.

Conclusions: Despite the increased reporting of depressive and anxious symptoms during the COVID-19 pandemic, there have been no changes in the dispensing trends of medications used to treat these disorders. As the pandemic continues to evolve, future research is needed to monitor the prevalence of depression and anxiety, and associated medication use, in the Canadian population.

Citing Articles

Impact of the COVID-19 pandemic on antidepressant consumption in the Central region of Portugal: interrupted time series.

Negrao L, Coelho C, Castel-Branco M, Figueiredo I, Fernandez-Llimos F Soc Psychiatry Psychiatr Epidemiol. 2024; 60(3):621-629.

PMID: 39001886 PMC: 11870879. DOI: 10.1007/s00127-024-02731-0.

The COVID-19 pandemic and the use of benzodiazepines and benzodiazepine-related drugs in Estonia: an interrupted time-series analysis.

Kurvits K, Toompere K, Jaanson P, Uuskula A Child Adolesc Psychiatry Ment Health. 2024; 18(1):66.

PMID: 38845001 PMC: 11157874. DOI: 10.1186/s13034-024-00757-5.

Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic.

Tiger M, Castelpietra G, Wesselhoeft R, Lundberg J, Reutfors J Transl Psychiatry. 2024; 14(1):175.

PMID: 38575574 PMC: 10995182. DOI: 10.1038/s41398-024-02894-z.

Impact of the COVID-19 pandemic on prescription drug use and costs in British Columbia: a retrospective interrupted time series study.

Zeitouny S, McGrail K, Tadrous M, Wong S, Cheng L, Law M BMJ Open. 2024; 14(1):e070031.

PMID: 38176877 PMC: 10773331. DOI: 10.1136/bmjopen-2022-070031.

Physician benzodiazepine self-use prior to and during the COVID-19 pandemic in Ontario, Canada: a population-level cohort study.

Myran D, Milani C, Pugliese M, Hensel J, Sood M, Kendall C BMJ Open. 2023; 13(4):e062742.

PMID: 37085307 PMC: 10123848. DOI: 10.1136/bmjopen-2022-062742.

References

Vindegaard N, Benros M . COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020; 89:531-542. PMC: 7260522. DOI: 10.1016/j.bbi.2020.05.048. View

Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M . Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health. 2020; 16(1):57. PMC: 7338126. DOI: 10.1186/s12992-020-00589-w. View

Bhatia R, Chu C, Pang A, Tadrous M, Stamenova V, Cram P . Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. CMAJ Open. 2021; 9(1):E107-E114. PMC: 8034297. DOI: 10.9778/cmajo.20200311. View

Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N . How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry. 2020; 7(9):813-824. PMC: 7365642. DOI: 10.1016/S2215-0366(20)30307-2. View

Chen S, She R, Qin P, Kershenbaum A, Fernandez-Egea E, Nelder J . The Medium-Term Impact of COVID-19 Lockdown on Referrals to Secondary Care Mental Health Services: A Controlled Interrupted Time Series Study. Front Psychiatry. 2020; 11:585915. PMC: 7726266. DOI: 10.3389/fpsyt.2020.585915. View

Brooks S, Webster R, Smith L, Woodland L, Wessely S, Greenberg N . The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020; 395(10227):912-920. PMC: 7158942. DOI: 10.1016/S0140-6736(20)30460-8. View

Moroz N, Moroz I, Slovinec DAngelo M . Mental health services in Canada: Barriers and cost-effective solutions to increase access. Healthc Manage Forum. 2020; 33(6):282-287. DOI: 10.1177/0840470420933911. View

Katzman M, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M . Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014; 14 Suppl 1:S1. PMC: 4120194. DOI: 10.1186/1471-244X-14-S1-S1. View

Xiong J, Lipsitz O, Nasri F, Lui L, Gill H, Phan L . Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020; 277:55-64. PMC: 7413844. DOI: 10.1016/j.jad.2020.08.001. View

10.

Gomes T, Mamdani M, Paterson J, Dhalla I, Juurlink D . Trends in high-dose opioid prescribing in Canada. Can Fam Physician. 2014; 60(9):826-32. PMC: 4162700. View

11.

Kennedy S, Lam R, McIntyre R, Tourjman S, Bhat V, Blier P . Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016; 61(9):540-60. PMC: 4994790. DOI: 10.1177/0706743716659417. View

12.

Ridout K, Alavi M, Ridout S, Koshy M, Harris B, Dhillon I . Changes in Diagnostic and Demographic Characteristics of Patients Seeking Mental Health Care During the Early COVID-19 Pandemic in a Large, Community-Based Health Care System. J Clin Psychiatry. 2021; 82(2). DOI: 10.4088/JCP.20m13685. View

13.

Abbott A . COVID's mental-health toll: how scientists are tracking a surge in depression. Nature. 2021; 590(7845):194-195. DOI: 10.1038/d41586-021-00175-z. View

14.

Nason I, Stein D, Frank R, Stein M . Decline In New Starts Of Psychotropic Medications During The COVID-19 Pandemic. Health Aff (Millwood). 2021; 40(6):904-909. DOI: 10.1377/hlthaff.2021.00028. View

15.

Rajkumar R . COVID-19 and mental health: A review of the existing literature. Asian J Psychiatr. 2020; 52:102066. PMC: 7151415. DOI: 10.1016/j.ajp.2020.102066. View

16.

McGinty E, Presskreischer R, Han H, Barry C . Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020. JAMA. 2020; 324(1):93-94. PMC: 7270868. DOI: 10.1001/jama.2020.9740. View

17.

Uthayakumar S, Tadrous M, Vigod S, Kitchen S, Gomes T . The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. Depress Anxiety. 2021; 39(2):156-162. PMC: 9015529. DOI: 10.1002/da.23228. View